Crohn's disease inflammatory bowel diseases ulcerative colitis
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Age 18 years to 70 years * Informed Consent (IC) * Established diagnosis of CD or UC for more than six months, based on clinical, endoscopic, radiologic and histologic characteristics
Exclusion criteria
Exclusion criteria: * Use of antibiotics 1 month prior to the trial * Extensive surgery for Crohn*s disease or ulcerative colitis* * Recent myocardial infarction or unstable angina pectoris * Suspected acute peritonitis or perforation * Pregnancy * Contraindications for harvesting biopsy specimens
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We expect to obtain proof of principle showing how the microbial composition of the intestine might be a biomarker for: - subtypes of inflammatory bowel disease - localization of inflammatory bowel disesase (as described in the Montreal classification) - activity of inflammatory bowel disease, and a potential early indicator of exacerbation | — |
Secondary
| Measure | Time frame |
|---|---|
| IS-pro, a novel powerful molecular bacterial profiling method will be validated to be introduced as a new high-throughput approach to characterize the intestinal microbiota in a routine laboratory setting. This technique will be compared to novel molecular profiling techniques, such as 454 pyrosequencing or qPCR as gold standard of characterization of complex microbial communities. For diagnostic application, profiles derived from standardized mucosal biopsy specimens will be compared to those derived from faecal samples and rectal swabs. With the comparison of these samples, we intend to verify the validity of faecal profiles as a proxy for mucosal profiles, thus providing a non-invasive diagnostic tool. | — |
Countries
Netherlands
Outcome results
None listed